
Opinion|Videos|May 8, 2024
Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials
Sarah Rockwell, PharmD, BCOP, provides an overview of the safety and efficacy data of bispecific antibodies investigated in the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 trials, providing critical insights into the results of each study.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Long COVID and Brain Health
2
Expert: Why Cutting Alcohol May Enhance GLP-1 Outcomes in Patients With Obesity and Diabetes Risk
3
Recapping 2025 ASHP Midyear: Expanding the Pharmacist’s Role in Patient Care, Technology, and Health System Resilience
4
Radio Frequency Identification is Revolutionizing Medication Management
5


















